All figures in Canadian dollars ($) unless otherwise specified Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - November 5, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTC: PCLOF) (" PharmaCielo " or the " Company "), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced its intention to extend expiry... Read More

All figures in Canadian dollars ($) unless otherwise specified Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - October 7, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) (" PharmaCielo " or the " Company "), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today made two corporate announcements.... Read More

All figures in Canadian dollars ($) unless otherwise specified Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - August 16, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) (" PharmaCielo " or the " Company "), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced financial results for the... Read More

Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - July 17, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTC Pink: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today provided shareholders with an update regarding reinstatement for trading on TSX Venture Exchange... Read More

The contract to supply the State of São Paulo is the largest public sector contract awarded to date in Brazil - the State of São Paulo is the largest state in the country. Ease Labs to supply up to 1.871 tons of pharma-grade CBD to the government over a 12-month period. Ease Labs' product is based on PharmaCielo's proprietary API. Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - March 26, 2024) - PharmaCielo Ltd.... Read More

Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - March 1, 2024) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today commented on the recent decision by the Colombian Ministries of Health, Justice, and... Read More

Austin, Texas and Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - January 4, 2024) - Benuvia Operations, LLC ("Benuvia"), a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, and PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo"), the Canadian parent of Colombia's premier cultivator, producer and global supplier of dried flower and medicinal-grade cannabis extracts,... Read More

All figures in Canadian dollars ($) unless otherwise specified Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - November 29, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) (" PharmaCielo " or the " Company "), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced financial results for the... Read More

Today the Company closed the latest tranche consisting of 1,500 units for aggregate proceeds of $1,500,000. The Company also announced that it has agreed to issue shares and debt in settlement of certain amounts owing. Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - October 6, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator... Read More

All figures in Canadian dollars ($) unless otherwise specified Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - August 29, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) (" PharmaCielo " or the " Company "), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced financial results for the... Read More

Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - August 10, 2023) - PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today provided shareholders with an update on several ongoing initiatives. Management Commentary... Read More

The Company has products in various stages of testing and sales with more than 40 customers in 11 countries, with continued growth expected for the year. Q1 2023 revenue of $786,498; Adjusted EBITDA loss of $1.9 million. PharmaCielo continues to focus on operating efficiently, with overhead expenses i down 20% from Q1 of 2022, and a recently initiated plan, which it expects will result in a reduction of the Company's... Read More

Represents PharmaCielo's first shipment to South Africa, which has well-established export networks in the UK and Australia, and other potential markets, globally. Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - May 16, 2023) - PharmaCielo Ltd . (TSXV: PCLO) (OTCQX: PCLOF) ("PharmaCielo" or the "Company"), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade... Read More

During 2022, PharmaCielo made shipments to 23 clients in 9 countries, with continued growth expected for 2023. The Company's measured investments in revenue-generating sales channels resulted in revenues of $5.3 million in 2022, almost three-times more than the $1.9 million reported in 2021. Consistent progress on streamlining the business, to move toward profitability - 2022 SG&A expenses represent a 40% reduction vs. 2021,... Read More

Will bring unique high-THC Colombian strains owned by PharmaCielo to Europe for the first time. Combines PharmaCielo's expertise in producing premium medicinal cannabis products, with CANNPRISMA's conversion capabilities, to bring patients in Europe the highest quality high-THC flower product currently available in the market. Toronto, Ontario and Rionegro, Colombia--(Newsfile Corp. - April 19, 2023) - PharmaCielo Ltd.... Read More

PharmaCielo has received a purchase order for CBD Isolate as an API, which will be used by a large pharmaceutical company in Brazil (the "Customer"), for final testing. The Customer has already qualified PharmaCielo as a supplier of API – the Company expects to begin shipping product on a commercial basis to the Customer by Q4 2023. TORONTO and RIONEGRO, Colombia , Feb. 8, 2023 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the... Read More

Steady progress against the efficiency plans initiated in mid-2021 with the transition to the current senior management team. Expects a reduction in its annualized fixed costs by approximately 25% compared to 2022 as a result of these ongoing efforts. The Company is focused on consistently reducing expenses and improving efficiency to facilitate a rapid transition to a cash flow positive position as its revenue continues to... Read More

Ease Labs Pharma, a global pharmaceutical company headquartered in Brazil , has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA) to launch its Canabidiol Ease Labs 100 mg/ml in Brazil beginning in January 2023 , and PharmaCielo's proprietary API was included as part of that approval. PharmaCielo has been shipping product to Ease Labs since 2021 in support of its product development efforts.... Read More

Represents PharmaCielo's first shipment to Africa . Morocco is pioneering the commercialization of cannabinoid products on the African continent and will be a growing market. The Company also announced that it has agreed to issue shares in settlement of certain interest payments and debt. TORONTO, Canada and RIONEGRO, Colombia , Dec. 5, 2022 /CNW/ - PharmaCielo Ltd . ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX:... Read More

TORONTO and RIONEGRO, Colombia , Nov. 22, 2022 /CNW/ - PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO, OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that the TSX Venture Exchange ("TSXV") has approved the extension of 9,007,200 warrants originally... Read More

In the first nine months of 2022, PharmaCielo has made shipments to 23 customers in nine countries, with continued growth expected for 2023. The Company has more than doubled Revenue to $3.8 million in the first nine months of 2022, compared to the first nine months of 2021. Consistent progress on streamlining the business, while investing in revenue-generating sales functions. SG&A expenses reduced by over 40% in the first... Read More

This is PharmaCielo's second pharmaceutical grade product shipment to a well-established Latin American pharmaceutical company with operations in Uruguay . PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF) the Canadian parent of Colombia's premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today... Read More

Shipment made to an established pharmaceutical distributor and clinical research organization in the Czech Republic , focused on medicinal grade cannabinoids PharmaCielo Ltd . ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried cannabis flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today... Read More

Colombian government has maintained its commitment to supporting its cannabis producers and building a dominant global export industry. Five tonne quota to grow THC-dominant cannabis strains for export as dried flower will support the fulfillment of current sales agreements, beginning in early 2023. PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier... Read More

The Company continues to grow sales and expects to build momentum through the remainder of 2022 and through 2023, with recent progress in Israel , Brazil and Mexico . PharmaCielo product has been sold in 14 countries to date, and the Company expects to increase this total to 17 countries by the end of 2022. PharmaCielo's previously announced non-brokered private placement of debenture units is oversubscribed for a total of... Read More

The Company expects to begin exporting dried flower to Israel in early 2023. Israel is one of the largest importers of medical cannabis in the world, with 109,352 active medical patients in 2021 (+35% vs. 2020) 1 . PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo... Read More

The Company has made a pre-commercial shipment of CBD isolate to its Mexican joint venture, to support product development by a Mexican phytotherapeutic company. PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced... Read More

PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced a supply agreement (the "Agreement") with one of the largest phyto-therapeutic companies in the Brazilian market (the "Customer"). The Customer has an extensive... Read More

The Company has shipped pre-commercial quantities of CBD full spectrum oil containing THC, to support the development of a full spectrum product for the Brazilian market. PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today... Read More

The Company expects Revenue to continue to grow – recently shipped 300 kg of CBD Full Spectrum Oil to a Spanish pharmaceutical company , announced entrance into Polish market , and shipments to Germany expected by late 2022. Steadily building pipeline in other key markets. Continued progress on streamlining the business, while continuing to invest in revenue-generating sales functions – SG&A expenses reduced by approximately... Read More

The Company has shipped pharmaceutical grade CBD full spectrum oil containing THC to Extractions Solutions SL, to support pre-commercial development of a full spectrum product for the European market. PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia... Read More

PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), announces today that, further to its previously announced non-brokered private placement of debenture units ("Units"), it is engaged in ongoing discussions with specific parties and expects to... Read More

Poland is one of the largest cannabis markets in Europe by patient population, with more than 28,000 prescriptions issued to approximately 10,000 patients in the first nine months of 2021 1 . The Company expects to begin shipping to Poland during the first half of 2023. PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried... Read More

Regulation to enable dried flower export and expand applications of CBD-based products passed by the Colombian Government on February 22, 2022 PharmaCielo's upstream and downstream scale and quality uniquely position the Company to be a dominant competitor with current suppliers of psychoactive flower to the EU and other markets. Executing on opportunities to streamline the business, while continuing to invest in... Read More

Builds on the passing of Regulation 227 in February, which implemented legal provisions to enable dried flower export and access to additional opportunities for CBD-based products. PharmaCielo expects to begin exporting dried flower in the second quarter of 2022, with volumes growing through the remainder of the year. PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of... Read More

PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today provided investors with an update on its non-brokered private placement of debenture units. As previously announced, the Company has completed the issuance of $5,000,000 principal amount... Read More

The Company will start supplying the German market with three THC-dominant products, with commercial shipments expected to begin in late 2022. This is PharmaCielo's first sales agreement related to THC products. Represents a significant milestone related to management's re-focusing of PharmaCielo's product strategy toward... Read More

PharmaCielo is actively working with, and has recently shipped product to, established companies in Argentina , Brazil , Colombia and Paraguay . The Company's sales and technical teams are providing support to these customers as they conduct testing and advance product registrations using PharmaCielo APIs i , to market.... Read More

All amounts expressed in Canadian dollars unless otherwise noted PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), is pleased to announce that... Read More

All amounts expressed in Canadian dollars unless otherwise noted PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S. ("Holdings"), today announced that it has... Read More

Received confirmation of Colombian GMP Certification for Phytotherapeutics manufactured with proprietary PharmaCielo extracts and cultivars. Currently working toward EU-GMP certification, expected to be achieved in the first half of 2022. Executing on opportunities to streamline the business – In the three months ended... Read More

GMP i certification has been confirmed by INVIMA. The certification covers Phytotherapeutics manufactured with PharmaCielo´s extracts and proprietary cultivars. PharmaCielo’s Processing and Extraction Centre – the largest in Colombia and one of the largest globally – has been in compliance with EU-GMP ii guidelines since February 2021 and the Company expects to achieve EU-GMP certification in H1-2022. PharmaCielo Ltd.... Read More

Mr. DeGabrielle was an early entrepreneur and executive in the U.S. cannabis industry; he founded and owns Los Sueños Farms LLC, the largest outdoor grow in North America , which he recently agreed to sell to Curaleaf, Inc. Mr. Nicholas is an experienced finance professional and an early investor in the global cannabis industry; he was one of the founding shareholders of Alternative Medical Enterprises LLC, which merged with... Read More

On track for Revenue growth in the back half of fiscal 2021, as recently signed sales agreements translate into higher volumes. Generated early revenue from more than ten countries in the quarter. Bill Petron , the Company's Chairman and a global operations and cannabis veteran, has been appointed Chief Executive Officer of... Read More

The Customer is focused on medicine development, manufacture and distribution, and is one of the first pharmaceutical players to be fully licensed by the Brazilian Health Regulatory Agency (ANVISA) to produce cannabis products in the country. Agreement covers two CBD-dominant formulations and two THC-dominant formulations. Represents continued traction in the Brazilian market following the Company's April 26 th announcement... Read More

The updated set of regulations opens doors for new cannabis-derived product categories to be developed and sold domestically and for export Decree addresses and closes regulatory gaps; improves Colombian cannabis industry's competitiveness on a global scale Opens the path for the development and sale of additional THC product types, as well as the commercial export of dried flower. PharmaCielo Ltd. ("PharmaCielo" or the... Read More

PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that Henning von Koss , Chief Executive Officer will participate in a discussion at the Cantor Fitzgerald International Cannabis Forum on June 28, 2021 . DETAILS Date: Monday, June 28, 2021.... Read More

Customer to use PharmaCielo's CBD Isolate for expanded research and development of an innovative sublingual product platform. PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that it has made an initial shipment of CBD Isolate (the... Read More

Most recently, Mr. Petron co-founded Alternative Medical Enterprises LLC, and co-led the company through its December 2020 merger with Verano Holdings LLC. PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis... Read More

PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO), (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today announced that experienced financial and cannabis executive Ian D. Atacan has been appointed Chief Financial Officer of the Company, effective June 7, 2021 , to replace CFO Scott Laitinen , who is... Read More

Recurring orders during Q1 2021 supported 31% Revenue growth compared to Q1 2020. Strong first quarter growth in demand for PharmaCielo's products, demonstrated by increased volume and repeat sales of CBD isolate and more complex products such as Broad-Spectrum Distillate. Continued growth in interest from potential customers in initiating GMP/EU GMP compliance audits, which the Company sees as one indicator of future... Read More

Mr. Petron has a diverse and successful background scaling global manufacturing, logistics and medical cannabis operations. Most recently, Mr. Petron co-founded Alternative Medical Enterprises LLC, and co-led the company through its December 2020 merger with Verano Holdings LLC. Current Chairman, Simon Langelier , has decided not to stand for re-election at the Company's Annual General and Special Meeting of Shareholders, to... Read More

Continues to advance sales pipeline – potential customers in Germany , Poland and Australia have scheduled EU-GMP and GMP 1 validation audits. Follows a recently completed GMP validation audit process by a large Brazilian Phyto-therapeutic customer in late April. PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade... Read More

FY 2020 Revenue of $2.7 million compared to $0.8 million in FY 2019. Achieved key milestones foundational to future commercial success: Completed one of the world's largest processing and extraction complexes 1 , introduced a broad cannabinoid product portfolio and began validation of GMP 2 and EU-GMP 2 standards with potential clients expanding access to pharmaceutical markets. Streamlined operations resulting in a... Read More

Shipments to established Pharmaceutical and Phyto-Therapeutics companies will offer PharmaCielo and its APIs 1 early integration into the supply chain. Shipments followed an audit by the Phyto-Therapeutics customer, that confirmed PharmaCielo's compliance with Brazilian GMP standards. PharmaCielo Ltd. ("PharmaCielo" or the... Read More

All figures are in Canadian dollars ($) unless otherwise specified PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., is pleased to announce the closing of its previously announced overnight marketed offering (the "Offering") of common shares (the "Common... Read More

Expects to close its previously announced overnight marketed equity financing on or about April 7, 2021 , for gross proceeds of approximately $12 million . All figures are in Canadian dollars ($) unless otherwise specified PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of... Read More

On March 10 th , Mexico's Chamber of Deputies voted 316 to 129 to advance a bill that would legalize recreational cannabis use in the country. With a population of more than 125 million people 1 and a potential market value of USD$3.2 billion 2 , Mexico is set to become the largest legal cannabis market in the world.... Read More

PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) (" PharmaCielo " or the " Company "), is pleased to announce the pricing of its previously announced overnight marketed offering (the " Offering ") of common shares (the " Common Shares ") from the treasury of the Company, at a price of $2.15 per Common Share (the " Offering Price "). The Company also announced that the size of the Offering has been increased to reflect gross... Read More

PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF) (" PharmaCielo " or the " Company "), is pleased to announce that it has filed a preliminary short form prospectus in connection with an overnight marketed offering (the " Offering ") of common shares (the " Common Shares ") from the treasury of the Company, at a price per Common Share to be determined in the context of the market (the " Offering Price ") for minimum gross... Read More

Shipped to existing Customer with operations in the U.K. and the E.U. THC-free broad-spectrum distillate from a single cultivar is a superior core formulation for nutraceutical and cosmetic formulations PharmaCielo is among the few global producers that deliver broad-spectrum formulations produced from specially selected, developed and standardized cultivars to B2B customers at consistently high quality and commercial scale.... Read More

Colombian and Mexican GMP certifications expected during Q1'21 and Q2'21, respectively The Company confirms that its recently completed Processing and Extraction Center at its Rionegro facility, Colombia's largest scale processing centre, will be producing extracts in compliance with EU-GMP guidelines by the end of February. PharmaCielo Ltd. ("PharmaCielo" or the "Company") (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of... Read More